Open AccessTHE RELEVANCE, BENEFITS AND CLINICAL PERSPECTIVES OF THE COMBINED TREATMENT OF OSTEOPOROSIS BASED ON BONE-ANABOLIC THERAPY
Author(s) -
Larisa Marchenkova,
М. И. Мартынова
Publication year - 2015
Publication title -
osteoporoz i osteopatii
Language(s) - English
Resource type - Journals
eISSN - 2311-0716
pISSN - 2072-2680
DOI - 10.14341/osteo2015220-24
Subject(s) - teriparatide , raloxifene , denosumab , osteoporosis , medicine , combination therapy , anabolic agents , pharmacotherapy , oncology , breast cancer , tamoxifen , bone mineral , cancer
Combination therapy of osteoporosis based on bone-anabolic and antiresorbtive agents has a great clinical perspective. An analysis of available publications shows that combination therapy is appropriate from the standpoint of increasing the effectiveness of treatment. Combination therapy can be executed as a simultaneous use of teriparatide with denosumab, raloxifene or hormonal therapy, and the subsequent administration of bisphosphonates, denosumab or raloxifene after treatment with teriparatide. The review presents the evidence-based data on the effect of combined and sequential regimens for osteoporosis fracture risk.